Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

EP-104GI Maintains 64% Remission Rate at 52 Weeks in Eosinophilic Esophagitis Trial

1 October 2026 · By · Wire by Fusion42

Published

1 October 2026

Topic

opportunities

◆ Sectors

BiotechDrug Discovery

◆ Source

Read at clinicaltrialvanguard.com →

◆ Verified

Fusion42 · 1 October 2026 · Fusion42 review

In Eupraxia’s RESOLVE trial for eosinophilic esophagitis, 64% of patients remained in clinical remission 52 weeks after a single dose of EP-104GI, showing sustained treatment efficacy.

This Wire brief sits within Fusion42's coverage of Biotech and Drug Discovery.

◆ ◆ The Wire takeaway

You can leverage sustained remission data from EP-104GI to differentiate your eosinophilic esophagitis treatment efforts from competitors. This trial outcome opens pathways for regulatory discussions that could accelerate market access.

◆ Coverage

1 source · 1 Oct 2026

◆ Related on Wire

◆ Topics

BiotechDrug Discoveryclinical-trialeosinophilic-esophagitisbiotechdrug-efficacyrare-disease